BMS and Sanofi mentioned in $1bn deal speculation over Biocon's oral insulin
This article was originally published in Scrip
Executive Summary
Speculation about early talks by Biocon, India's largest biotechnology company by revenue, to license out its oral insulin candidate has put the spotlight back on the firm, although there are mixed views on the prospects of a high-value deal, at least for now.